| Identification | Back Directory | [Name]
revatropate | [CAS]
149926-91-0 | [Synonyms]
166
UK-112
Uk-112,166
Revatropate
Unii-3W7L15V40w
(3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate
Benzeneacetic acid, α-(hydroxymethyl)-α-[2-[(R)-methylsulfinyl]ethyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (αS)-
(aS)-alpha-(Hydroxymethyl)-alpha-[2-[(R)-methylsulfinyl]ethyl]benzeneacetic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester
Benzenacetic acid, alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)-, 1-azabicyclo(2.2.2)oct-3-yl ester, (3R-(3R*(S*(R*))))- | [Molecular Formula]
C19H27NO4S | [MDL Number]
MFCD00919808 | [MOL File]
149926-91-0.mol | [Molecular Weight]
365.491 |
| Hazard Information | Back Directory | [Uses]
Revatropate is an antimuscarinic compound. Revatropate has a much greater inhibitory effect on M1 and M3 receptors than on the M2 subtype. Revatropate is used in the study of urge urinary incontinence and functional bowel disorders[1]. | [IC 50]
mAChR1; mAChR2; mAChR3 | [References]
[1] Alabaster VA. Discovery & development of selective M3 antagonists for clinical use. Life Sci. 1997;60(13-14):1053-60. DOI:10.1016/s0024-3205(97)00047-7 |
|
|